Novartis to study hydroxychloroquine for Covid-19

20th April 2020 (Last Updated April 20th, 2020 12:06)

Novartis has entered an agreement with the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of hydroxychloroquine to treat hospitalised patients with Covid-19.

Hydroxychloroquine, which is commonly used to treat malaria and some autoimmune diseases, showed anti-SARS-CoV-2 activity in laboratory tests.

Sponsored by Novartis, the new Phase III trial will assess hydroxychloroquine as a potential Covid-19 therapy in around 440 participants.

Read the full article here